Calcitriol protects renovascular function in hypertension by down-regulating angiotensin II type 1 receptors and reducing oxidative stress

European Heart Journal

Volumn 33, Issue 23, 2012, Pages 2980-2990

  Dong, Jinghui ^a,b   Wong, Siu Ling ^a   Lau, Chi Wai ^a   Lee, Hung Kay ^a   Ng, Chi Fai ^a   Zhang, Lihong ^a   Yao, Xiaoqiang ^a   Chen, Zhen Yu ^a   Vanhoutte, Paul M ^c,d   Huang, Yu ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Calcitriol; Endothelial dysfunction; Hypertension; Oxidative stress; Vitamin D

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN 1 RECEPTOR; CALCITRIOL; PROTEIN P67; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SUPEROXIDE DISMUTASE; VITAMIN D RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; MALE; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR DOWN REGULATION; RENAL ARTERY; RENOVASCULAR DISEASE; VASODILATATION;

ANIMALS; AORTA; CALCITRIOL; CELLS, CULTURED; DACTINOMYCIN; DOWN-REGULATION; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION, RENOVASCULAR; MALE; OXIDATIVE STRESS; OXIDOREDUCTASES; PROTEIN SYNTHESIS INHIBITORS; RATS; RATS, INBRED SHR; RATS, WISTAR; REACTIVE OXYGEN SPECIES; RECEPTOR, ANGIOTENSIN, TYPE 1; RENAL ARTERY; VITAMINS;

EID: 84865663428     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr459     Document Type: Article

References (40)

1. Holick MF. Evolution and function of vitamin D. Recent Results Cancer Res 2003; 164:3-28.
2. Norman AW. Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology 2006;147:5542-5548.
3. Pilz S, Tomaschitz A, Ritz E, Pieber TR. Vitamin D status and arterial hypertension: a systematic review. Nat Rev Cardiol 2009;6:621-630.
4. Lee JH, O'Keefe JH, Bell D, Hensrud DD, Holick MF. Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor?. J Am Coll Cardiol 2008;52:1949-1956.
5. Drechsler C, Pilz S, Obermayer-Pietsch B, Verduijn M, Tomaschitz A, Krane V, Espe K, Dekker F, Brandenburg V, März W, Ritz E, Wanner C. Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J 2010;31:2253-2261.
6. Zittermann A, Schleithoff SS, Koerfer R. Vitamin D and vascular calcification. Curr Opin Lipidol 2007;18:41-46.
7. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008;168:397-403.
8. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 2008;168: 1174-1180.
9. Li YC, Kong J, Wei MJ, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110:229-238.
10. Yuan W, Pan W, Kong J, Zheng W, Szeto FL, Wong KE, Cohen R, Klopot A, Zhang Z, Li YC. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 2007;282:29821-29830.
11. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alphahydroxylase knockout mice. Kidney Int 2008;74:170-179.
12. Wong MS, Delansorne R, Man RY, Svenningsen P, Vanhoutte PM. Chronic treatment with vitamin D lowers arterial blood pressure and reduces endotheliumdependent contractions in the aorta of the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 2010;299:H1226-H1234.
13. Wong MS, Delansorne R, Man RY, Vanhoutte PM. Vitamin D derivatives acutely reduce endothelium-dependent contractions in the aorta of the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 2008;295:H289-H296.
14. Wu-Wong JR. Potential for vitamin D receptor agonists in the treatment of cardiovascular disease. Br J Pharmacol 2009;158:395-412.
15. Mancuso P, Rahman A, Hershey SD, Dandu L, Nibbelink KA, Simpson RU. 1,25-dihydroxyvitamin-D3 treatment reduces cardiac hypertrophy and left ventricular diameter in spontaneously hypertensive heart failure-prone (cp/+) rats independent of changes in serum leptin. J Cardiovasc Pharm 2008;51:559-564.
16. Vanhoutte PM, Shimokawa H, Tang EH, Feletou M. Endothelial dysfunction and vascular disease. Acta Physiol (Oxf) 2009;196:193-222.
17. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs 2002;62:265-284.
18. Schiffrin EL. Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens 2001;14:83S-89S.
19. US Renal Data System. USRDS 2005 Annual Data Report. Bethesda MUNIoH: National Institute of Diabetes and Digestive and Kidney Diseases; 2005.
20. Wong WT, Tian XY, Chen ZY, Leung FP, Liu LM, Lee HK, Nq CF, Xu AM, Yao XQ, Vanhoutte PM, Tipoe GL, Huang Y. Bone morphogenic protein-4 impairs endothelial function through oxidative stress-dependent cyclooxygenase-2 upregulation implications on hypertension. Circ Res 2010;107: 984-991.
21. Wong SL, Lau CW, Wong WT, Xu AM, Au CL, Nq CF, Nq SS, Gollasch M, Yao XQ, Huang Y. Pivoted role of protein kinase Cd in angiotensin II-induced endothelial cyclooxygenase-2 expression: a link to vascular inflammation. Arterioscler Thromb Vasc Biol 2011;31:1169-1176.
22. Yuen CY, Wong WT, Tian XY, Wong SL, Lau CW, Yu J, Tomlinson B, Yao XQ, Huang Y. Telmisartan inhibits vasoconstriction via PPARg-dependent expression and activation of endothelial nitric oxide synthase. Cardiovasc Res 2011;90: 122-129.
23. Wong SL, Leung FP, Lau CW, Au CL, Yung LM, Yao XQ, Chen ZY, Vanhouttr PM, Gollasch M, Huang Y. Cyclooxygenase-2-derived prostaglandin F2a mediates endothelium-dependent contractions in the aortae of hamsters with increased impact during aging. Circ Res 2009;104:228-235.
24. Münzel T, Gori T, Bruno RM, Taddei S. Is oxidative stress a therapeutic target in cardiovascular disease?. Eur Heart J 2010;31:2741-2748.
25. Vanhoutte PM. Endothelium-dependent contractions in hypertension when prostacyclin becomes ugly. Hypertension 2011;57:526-531.
26. Vanhoutte PM, Feletou M, Taddei S. Endothelium-dependent contractions in hypertension. Br J Pharmacol 2005;144:449-458.
27. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. Endothelium-dependent contractions and endothelial dysfunction in human hypertension. Br J Pharmacol 2009; 157:527-536.
28. Knight SF, Yuan JH, Roy S, Imig JD. Simvastatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension. Am J Physiol-Renal 2010;298:F86-F94.
29. Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Kim HS, Shin MS, Ahn TH, Choi IS, Shin EK. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003;42:905-910.
30. Schmieder RE. Mechanisms for the clinical benefits of angiotensin II receptor blockers. Am J Hypertens 2005;18:720-730.
31. Qiao GL, Kong J, Uskokovic M, Li YC. Analogs of 1 alpha,25- dihydroxyvitamin D3 as novel inhibitors of renin biosynthesis. J Steroid Biochem 2005;96:59-66.
32. Kong J, Kim GH, Wei MJ, Sun T, Li G, Liu SQ, Li XM, Bhan I, Zhao Q, Thadhani R, Li YC. Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats. Am J Pathol 2010;177:622-631.
33. Díaz L, Noyola-Martínez N, Barrera D, Hernández G, Avila E, Halhali A, Larrea F. Calcitriol inhibits TNF-alpha-induced inflammatory cytokines in human trophoblasts. J Reprod Immunol 2009;81:17-24.
34. Sánchez-Martínez R, Zambrano A, Castillo AI, Aranda A. Vitamin D-dependent recruitment of corepressors to vitamin D/retinoid X receptor heterodimers. Mol Cell Biol 2008;28:3817-3829.
35. Lassègue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 2003;285:R277-R297.
36. Félétou M, Huang Y, Vanhoutte PM. Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol 2011;164:894-912.
37. Husain K, Suarez E, Isidro A, Ferder L. Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas. Am J Nephrol 2010;32:296-304.
38. Michel FS, Man GS, Man RY, Vanhoutte PM. Hypertension and the absence of EDHF-mediated responses favour endothelium-dependent contractions in renal arteries of the rat. Br J Pharmacol 2008;155:217-226.
39. Freundlich M, Quiroz Y, Zhang Z, Zhang Y, Bravo Y, Weisinger JR, Li YC, Rodriguez-lturbe B. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008;74:1394-1402.
40. Krause R, Bühring M, Hopfenmüller W, Holick MF, Sharma AM. Ultraviolet B and blood pressure. Lancet 1998;352:709-710.